相同組換え欠損を評価するための方法および材料

Japanese Patent JP6877334

B2

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

JP6291721	Microbial inspection method
JP2018530317	Methods and compositions for regulating PRFA-mediated pathogen gene activation in Listeria monocytogenes
JP6706416	Microalgae culture method and data analysis device

Abu Kevic Victor
Tims kirstin
Gutin Alexander
Lead julia

JP2017508488A

May 26, 2021

August 17, 2015

Click for automatic bibliography generation  

Myriad Genetics, Inc.

C12Q1/06; A61K31/166; A61K31/282; A61K31/4745; A61K31/704; A61K33/24; A61K45/00; A61P35/00; C12N5/09; C12Q1/6827; G01N33/574

WO2013130347A1
WO2012027224A1
WO2013096843A1

Myriad Genetics, Inc., Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study, [online], December 14, 2013,
Cancer Research, 2012, Vol.72, No.21, pp.5454-5462
日本産科婦人科学会雑誌, 2008, Vol.60, No.11, pp.1844-1854
British Journal of Cancer, 2012, Vol.107, pp.1776-1782
Cancer Discovery, 2012, Vol.2, No.4, pp.366-375
MLO Staff, Myriad presents data on BRXAnalysis CDx and HRD at 2014 ASCO meeting, [online], June 2, 2014,

Hatsushi Shimizu
Masao Haruna
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Kazuya Kawamoto

Previous Patent: プラズマ処理システム用のコンパクトな構成可能なモジュール式高周波整�...

Next Patent: 二倍長の半製品を中間的に保管するための方法および器具